Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1997-3-28
pubmed:abstractText
The efficacy and tolerability of vigabatrin as add-on therapy was assessed in patients with uncontrolled partial seizures. Ninety-seven patients entered this seven-centre, double-blind, placebo-crossover study. Vigabatrin (2 g or 3 g) or placebo was administered daily. Vigabatrin was well-tolerated and did not cause clinically significant adverse drug effects when added to established anticonvulsant therapy. No significant differences were observed between dose groups for the overall incidence of adverse events, although drowsiness and visual disturbances (diplopia, ataxia, visual abnormalities) showed a dose-related increase with vigabatrin treatment. The results of this study indicate that vigabatrin, given in a daily dose of either 2 g or 3 g is significantly more effective than placebo in reducing seizure frequency among patients with partial seizures.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1059-1311
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
259-65
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:8952010-Adolescent, pubmed-meshheading:8952010-Adult, pubmed-meshheading:8952010-Aged, pubmed-meshheading:8952010-Anticonvulsants, pubmed-meshheading:8952010-Cross-Over Studies, pubmed-meshheading:8952010-Dose-Response Relationship, Drug, pubmed-meshheading:8952010-Double-Blind Method, pubmed-meshheading:8952010-Drug Administration Schedule, pubmed-meshheading:8952010-Drug Therapy, Combination, pubmed-meshheading:8952010-Electroencephalography, pubmed-meshheading:8952010-Epilepsy, Complex Partial, pubmed-meshheading:8952010-Female, pubmed-meshheading:8952010-Humans, pubmed-meshheading:8952010-Male, pubmed-meshheading:8952010-Middle Aged, pubmed-meshheading:8952010-Treatment Outcome, pubmed-meshheading:8952010-Vigabatrin, pubmed-meshheading:8952010-gamma-Aminobutyric Acid
pubmed:year
1996
pubmed:articleTitle
A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures.
pubmed:affiliation
Austin Hospital, Heidelberg, Victoria, Australia.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial